REG - Angle PLC - ANGLE announces collaboration with Myriad Genetics

AngleAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250820:nRST9557Va&default-theme=true

RNS Number : 9557V  Angle PLC  20 August 2025

 For immediate release  20 August 2025

 

ANGLE plc ("the Company")

 

COLLABORATION WITH MYRIAD GENETICS

 

Assessment of feasibility for use of Parsortix derived circulating tumour cell
(CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is delighted to announce that it has
entered a collaboration with Myriad Genetics, Inc. (MYGN:NSQ), a leading
molecular diagnostic testing and precision medicine company dedicated to
advancing health and well-being for all.

 

Under the terms of the agreement, blood samples from cancer patients will be
processed by ANGLE's research and development team utilising the Parsortix(®)
system for the capture and harvest of intact cancer cells for downstream
molecular analysis. Results for this analysis will compare CTC-DNA with
matched patient tissue samples using Myriad Genetics' existing tissue-based
assay.

 

Further details of the agreement are confidential between the parties.

 

 

ANGLE Chief Executive, Andrew Newland, commented:

"We are delighted to be working with Myriad Genetics, a major player in
tissue-based companion diagnostic tests, seeking to extend their tests to work
on a simple blood test using CTCs harvested by the Parsortix system.  We look
forward to working with Myriad Genetics to progress this collaboration which
has the potential to have a substantial impact on patient treatment by
improving access to actionable genomic data."

 

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://protect.checkpoint.com/v2/r01/___https:/angleplc.com/investor-relations/glossary/___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6bzo0NWNkOTlkNDliOTlmNDBjMjE5MmQyMjYwODBkNjJjMDo3OjYwOTM6MDNiYTZjZjg5YTJiZGQ1NGE4YjNhYjdkNzkxZWMyZDQzNTcxNmVjNTllMzdjMTY5NDMzZDgyMGMzMjgxMjliYTpwOlQ6Tg)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system, associated
consumables and assays. The clinical services business is offered through
ANGLE's GCLP-compliant laboratories.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 110 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(https://protect.checkpoint.com/v2/r01/___http:/www.angleplc.com___.YzJ1Om15cmlhZGdlbmV0aWNzOmM6bzo0NWNkOTlkNDliOTlmNDBjMjE5MmQyMjYwODBkNjJjMDo3OmI1YTc6MTFiNjRjMDZiNjQ0YWI4ZDA4OGQ1ZDVjN2FjNzU4YTQzMWY3ZmE1MjliYmQzNWYwMTM3YTY1ZGZhODI0MGY0MDpwOlQ6Tg)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEALPNFFSSEFA